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Abstract
Background: NLRP3-inflammasome activation was evaluated in monocyte-derived dendritic cells (DC) obtained through
IL-4 (IL4-DC) or IFN-α (IFN-DC) protocols and pulsed with chemically inactivated HIV-1. Inflammasome’ genes expression
and IL-1β secretion were compared in DC isolated from 15 healthy subjects (HC) and 10 HIV-1 infected individuals (HIV+).
Findings: Whether HIV was able to increased NLRP3-inflammasome genes expression and IL-1β secretion in IL4-DC from
HC, the induction of inflammasome appeared significantly reduced in IFN-DC from HC, suggesting a different responsive
state of IFN-DC compared to IL4-DC. No inflammasome activation was observed in IL4-DC as well as in IFN-DC derived
from HIV + subjects, confirming previous findings on “unresponsive” state of DC derived from HIV + possibly due to
chronic inflammatory state of these individuals.
Conclusions: Our results showed that IFN-α differently modulates inflammasome expression during monocytes-DC
in vitro differentiation. These findings could be of interest considering the on-going research about DC manipulation
and therapeutic strategies for HIV + involving DC-based immune-vaccines.
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Findings
Background and aim
In the past ten years an increasing number of dendritic
cell (DC)-based therapeutic vaccination trials against
HIV-1 has been developed augmenting the general inter-
est in dendritic cell biology and in the interaction
between this innate immune cell and HIV-1 [1].
There are at least two major subtypes of DC: myeloid
and plasmacytoid DC. Myeloid DC (mDC) are profes-
sional antigen presenting cell capable to initiate cellular
immune response. On the other hand plasmacytoid DC
(pDC) exhibit an exuberant anti-viral response through
the production of high levels of IFN-alpha [2].
In HIV infection it has been demonstrated a reduction in
absolute number of mDC and pDC, especially in patients
with active HIV-1 replication [3], suggesting a key role
of DC in controlling viral load. Moreover the preserved
functionality of pDC isolated from “elite controllers” may
be one of the mechanisms involved in the control of HIV-1
viremia in these subjects [4].
Myeloid DC obtained culturing peripheral blood mono-
cytes with IL-4 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (IL4-DC) have been implied
in immunotherapy of cancer and, most recently, of HIV
infection [5].
Alternative protocols for maturation of DC included
the use of interferon (IFN)-α instead of IL-4 (IFN-DC).
Type I interferons markedly promotes the differentiation
of peripheral blood monocytes into DC. IFN-DC are
able to induce a strong cytotoxic response and cross
priming of CD8+ T cells against viral or tumoral anti-
gens both in vitro and in vivo [6,7]. IFN-DC exhibit a
combined phenotype of mDC and pDC associated with
characteristics of natural killer (NK) cells [8,9].
In the context of therapeutic vaccine against HIV-1,
the possibility of using IFN-DC would provide several
advantages, including augmented antigen presentation,
cytotoxic function and type I IFN production.
Considering the key role of NLRP3-inflammasome
during maturation and activation of DC in mice [10],
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our group has recently started working on inflamma-
some activation in DC obtained in vitro from peripheral
blood monocytes. DC response to HIV-1 through
NLRP3-inflammasome could be important in HIV
vaccine development especially in DC-based immune
treatment.
We demonstrated that human monocyte-derived
IL4-DC presented an inducible activation of NLRP3-
inflammasome by lipopolysaccharide/LPS as well as by
HIV-1 [10]. It is interesting to note that the same dif-
ferentiation protocol used in monocytes isolated from
HIV + individuals (HIV-DC) showed a different re-
sponse. NLRP3-inflammasome was not induced by LPS
or HIV in HIV-DC, however its basal activation re-
sulted higher in these cells compared with DC from
healthy subjects (HC-DC), letting us hypothesize an
“unresponsive” condition of HIV-DC that may affect
vaccine preparation [10].
In this study we investigate the rate of inflammasome
expression and activation in monocyte-derived IFN-DC
obtained from healthy individuals and HIV + patients. Our
findings could be of interest considering the on-going re-
search about DC manipulation and therapeutic strategies
for AIDS involving DC-based immune-vaccines.
Individuals and methods
15 healthy subjects (HC, 7 males, 8 females; mean age
30 ± 5 standard deviation/SD) and 10 HIV-1-positive
volunteers (HIV+, 8 males, 2 females; mean age 28 ± 2
SD) were recruited from “Hospital das Clinicas” (Univer-
sity of São Paulo, Brazil). HIV + patients had a CD4+
lymphocytes count > 500 cells/μl and were “naïve” for
treatment. All the patients have been infected for more
than 5 years and they do not presented specific clinical
symptoms at the moment of recruitment. Written in-
formed consent was obtained according to the protocol
of “Hospital das Clinicas” Ethical Committee (CAPPesq)
(São Paulo, Brazil).
Monocytes were isolated by adherence from periph-
eral blood monocytes obtained by centrifugation over
Ficoll-Paque gradient and cultured at 1.5-2 × 106/ml in
AIM-V medium (Gibco) containing 50 ng/ml GM-CSF
(Peprotech) and 50 ng/ml IL-4 (Peprotech) or IFN-α
(Schering-Plough) (IL4-DC and IFN-DC, respectively).
On day 5, DC were pulsed with 0.5 × 109 particles of
alditrithiol-2 inactivated HIV (as reported in [10]) for
4 hours. Supernatants were harvested and used for IL-1β
secretion dosage; cells were lysed for mRNA isolation and
gene expression analysis.
Figure 1 Inflammasome genes expression in IL4-DC and IFN-DC from healthy subjects pulsed with HIV-1. mRNA expression 4 hours after
stimulation of IL4-DC and IFN-DC with chemically inactivated HIV-1 was reported for NLRP1, NLRP3, NLRC4, AIM2, CASP1 and IL1B genes (1A).
Fold-change (FC) in mRNA expression of each gene was calculated with respect to the untreated condition as 2-ΔΔCt where ΔΔCt = ΔCt HIV- ΔCt
Untreated. Results are expressed as average (AVG) of 2-ΔΔCt ± standard error, n = 20. All the Ct values were normalized against ACTB Ct (ΔCt).
Stacked lines showed FC threshold (0.5-1.5). 1-way Anova analysis was used to compare genes expression in IFN-DC and IL4-DC. * = p < 0.05.
(1B) Supernatants of IFN-DC and IL4-DC stimulated or not with HIV-1 were analysed for the presence of secreted IL-1β. Results are expressed as
the average concentration (pg/ml) ± standard error. 1-way Anova analysis was used to compare IFN-DC and IL4-DC. * = p < 0.05.
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Total RNA was isolated using the RNAqueous micro kit
(Ambion, Life Technologies) and retro-transcribed with the
SuperScritp-II kit (Invitrogen). NLRP1, NLRP3, NLRC4,
AIM2, CASP1, IL1B genes were amplified with specific
TaqMan® Gene Expression Assays (Applied Biosystems)
using the ABI 7300 platform (Applied Biosystems). ACTB
was the housekeeping gene used for normalization. Fold-
change (FC) genes expression was calculated comparing
stimulated (+HIV) and untreated/resting cells as 2−ΔΔCt
following the indications of Livak et al. [11].
The secreted IL-1β was evaluated with ELISA (BD
Biosciences Pharmigen). Results were expressed as pg/ml.
One-way Anova analysis was used to compare differ-
ent groups and a significance level of 0.05 was applied.
Prism 5.01 software (GraphPad Software, Inc) was used
for done graphs and statistical analysis.
Results and discussion
We evaluated the expression of NLRP1, NLRP3, NLRC4,
AIM2, CASP1, IL1B genes in DC from 15 healthy subjects
obtained through IL-4 or IFN-α differentiation protocol and
pulsed with chemically inactivated HIV-1. IL-1β secretion
was also evaluated as marker of inflammasome activation.
Cells differentiation state was checked by flow cytome-
try looking at granulosity and common DC markers
(Additional file 1: Figure S1). No significant differences
were observed in differentiation markers between IL4-
DC and IFN-DC.
When genes expression was evaluated the following cri-
teria were applied: only samples with Ct < 35 and with a
positivity of at least 80% of the samples were included in
the analysis; normalized data (ΔCt) must be homogenous
for all the genes in each group (t test p-value > 0.05); FC >
1.5 or <0.5 were taken in account as up-regulation or
down-regulation.
HIV induced increased expression (FC > 1.5) of NLRP1,
NLRP3, AIM2, CASP1 and IL1B in IL4-DC, and of
NLRC4, AIM2, CASP1 and IL1B in IFN-DC (Figure 1A).
However the rate of induction appeared to be significantly
reduced in IFN-DC compared to IL-4 DC (p < 0.003).
Of note HIV-1 was able to increase NLRP3 expression
in IL4-DC (FC = 22.47), but it was not able to do the
same in IFN-DC (FC = 1.24) (p < 0.003) (Figure 1A).
These differences in inflammasome genes expression
between IL4-DC and IFN-DC were emphasized by the
results obtained from IL-1β secretion analysis in DC
supernatants. HIV induced a significant increase of the
pro-inflammatory cytokine in IL4-DC (+HIV = 186.5 pg/
ml versus Untreated = 74.87 pg/ml; p = 0.026) but not in
IFN-DC (+HIV = 21,88 pg/ml versus Untreated = 8,65 pg/
Figure 2 Inflammasome genes expression in IL4-DC and IFN-DC from HIV + subjects pulsed with HIV-1. mRNA expression 4 hours after
stimulation of IL4-DC and IFN-DC with chemically inactivated HIV-1 was reported for NLRP1, NLRP3, NLRC4, AIM2, CASP1 and IL1B genes (2A).
Fold-change (FC) in mRNA expression of each gene was calculated with respect to the untreated condition as 2-ΔΔCt where ΔΔCt = ΔCt HIV- ΔCt
Untreated. Results are expressed as average (AVG) of 2-ΔΔCt ± standard error, n = 20. All the Ct values were normalized against ACTB Ct (ΔCt).
Stacked lines showed FC threshold (0.5-1.5). 1-way Anova analysis was used to compare genes expression in IFN-DC and IL4-DC. * = p < 0.05.
(2B) Supernatants of IFN-DC and IL4-DC stimulated or not with HIV-1 were analysed for the presence of secreted IL-1β. Results are expressed as
the average concentration (pg/ml) ± standard error. 1-way Anova analysis was used to compare IFN-DC and IL4-DC.
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ml; p = 0.301) (Figure 1B). Basal secretion of IL4-DC
appeared augmented compared to IFN-DC however not
in a statistically significant way.
These findings suggested that chemically inactivated
HIV-1 is able to induce NLRP3-inflammasome activa-
tion in IL4-DC but not in IFN-DC.
As we previously hypothesized [10] NLRP3-inflammasome
could play a role in response against HIV and could par-
ticipate to full dendritic cell activation and to increased
proliferation of specific HIV-induced T cells. However our
new findings point out that the protocol implied to differ-
entiate monocytes to DC could affect inflammasome biol-
ogy. Our results agreed with previously reported data by
Guarda et al. [12] about the ability of type I IFNs to sup-
press pro-IL-1 levels and decrease the activity of NLRP1
and NLRP3-inflammasomes in mice. Moreover it is well
known that the activation of NLRP3-inflammasome in DC
is related with the ability to induce a Th17 polarization in
naïve T cells [13], while IFN-DC are able to induce Th1
but fail to polarize naïve T cells into Th17 [14], letting us
hypothesize that in IFN-DC the inflammasomes are not
induced.
When DC derived from HIV + individuals were ana-
lysed, we observed that HIV was not able to significantly
induce any of the inflammasome genes in IL4-DC as
well as in IFN-DC (1.5 < FC < 0.5) (Figure 2A). Accord-
ing to our previous published data [10], in untreated
cells IL1-β secretion was higher in HIV-DC compared to
HC-DC whatever protocol was used (Figure 1B and 2B;
p = 0.02). Moreover HIV was not able to induce aug-
mented amount of cytokine in IFN-DC or in IL4-DC
(Figure 2B). We have previously hypothesized that IL4-
DC from HIV + individuals presented an increased basal
activation of NLRP3-inflammasome possibly due to the
well-known chronic inflammatory state of HIV + pa-
tients leading to an “unresponsive” state of monocyte-
derived DC [10]. Our findings emphasized once more
that this condition is independent of the protocol used
for monocyte-DC differentiation.
We are aware that this study is preliminary and that
deep investigation about the functionality of IFN-DC is
needed, such as ability to activate a lymphocytes spe-
cific response, but we would emphasize the importance
of DC differentiation protocol in experimental design.
Moreover, considering the on-going trials of DC-based
immune treatment against HIV-1 [15] it is interesting
to remember that the in vitro manipulation of DC
could be a limited step in vaccine preparation. Whether
it will be fully demonstrated the role of NLRP3-
inflammasome in human DC maturation/activation
and the impact of inflammasome induction in lympho-
cyte specific response, our findings suggest that proto-
cols using IL-4 may represent a better choice than IFN
ones.
Additional file
Additional file 1: Figure S1. Characterization of monocyte-derived
dendritic cells. Generated immature monocyte-derived dendritic cells
obtained through IFN (IFN-DC) (A) or IL-4 (IL4-DC) (B) protocols for common
markers expression (CD11c, HLA-DR, CD80, CD86, CD83, CD1a, CCR7). Cells
were CD14 negative. Average percentage of positive cells and standard error
were reported for healthy individuals (n = 15) stimulated or not with HIV
(+HIV and Untreated, respectively).
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